The offering involves 1,833,334 ordinary shares paired with an equal number of Series D and Series E warrants. These warrants, exercisable immediately at $3.00, carry staggered expiration dates of one and five years. A.G.P./Alliance Global Partners served as the sole placement agent for the transaction, which is expected to close on or about June 18, 2026, pending customary conditions.
IceCure Medical Raises $5.5 Million in Premium Private Placement
IceCure Medical, the Caesarea-based developer of tumor-freezing cryoablation technology, has secured $5.5 million through a private placement with a single healthcare-focused institutional investor. The deal includes shares and warrants priced at $3.00 each, a valuation that sits at a premium to the company’s previous closing price on the Nasdaq.
Beyond the immediate capital injection, the company plans to use the proceeds for general working capital. IceCure also signaled a potential shift in its capital structure, reaching an agreement to lower the exercise price of March 2026 warrants from $16.50 to $3.00 per share, contingent on receiving necessary shareholder approval. These moves come as the company continues to market its ProSense system, a liquid-nitrogen-based platform designed as a minimally invasive alternative to traditional surgical tumor removal for breast, kidney, lung, and bone cancers.
Comments (0)
No comments yet. Be the first!